Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 30, 2014. The report serves as an announcement regarding a regulatory submission made jointly with Theravance, Inc. to the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a current report focused on a specific corporate event rather than a financial statement.
Material Changes and Corporate Events
- Regulatory Submission: GSK and Theravance submitted a supplemental New Drug Application (sNDA) to the FDA for Breo Ellipta (fluticasone furoate/vilanterol).
- Indication Expansion: The submission seeks approval for the treatment of asthma in patients aged 12 years and older, expanding beyond the existing approval for Chronic Obstructive Pulmonary Disease (COPD).
- Dosing Regimens: The application covers two dose regimens: 100/25mcg and 200/25mcg, administered once daily via the Ellipta dry powder inhaler.
- Clinical Basis: The filing is supported by data from 48 clinical pharmacology studies involving 1,328 subjects and 23 clinical studies involving 12,051 asthma patients.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The submission represents a strategic move to address the unmet needs of asthma patients, noting that more than half of patients continue to experience poor control despite medical advances.
Risks and Safety Information: The filing includes extensive safety warnings regarding Breo Ellipta, including:
- Class Effect Risk: Long-acting beta 2-adrenergic agonists (LABAs) like vilanterol increase the risk of asthma-related death.
- Contraindications: The drug is contraindicated for severe hypersensitivity to milk proteins or specific ingredients and should not be used for acute bronchospasm.
- Adverse Reactions: Common reactions include nasopharyngitis, upper respiratory tract infection, headache, and oral candidiasis. Serious risks include pneumonia (some fatal), adrenal insufficiency, and cardiovascular effects.
- Forward-Looking Statements: Both GSK and Theravance caution that actual results may differ materially from projections due to regulatory delays, clinical study outcomes, and collaboration risks.
Investor Verification Checklist
- Verify the FDA's review timeline and decision status for the Breo Ellipta asthma sNDA.
- Confirm the commercial impact of the asthma indication on GSK's respiratory portfolio revenue projections.
- Review the specific terms of the collaboration agreement between GSK and Theravance regarding royalty revenues for this product.
- Monitor any post-marketing safety data or FDA communications regarding the asthma-related death risk associated with LABAs.